“CannPal is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant”
Leaders inAnimal Therapeutics
Developing regulatory approved first-in-class animal pharmaceuticals to provide a new standard of care in animal health
A LEADING RESEARCH NETWORKSome of the world brightest minds
We’re fast-tracking R&D by leveraging validated medical cannabis research on humans and adapting it to animal health.
MAKING A DIFFERENCEEvery companion animal deserves to be cared for
We’re focused on making a difference in the animal health industry with products that are safe and proven to work
The animal population is ageing and age related disease is growing at a quicker rate than new product innovation and development.
It’s estimated that over 60% of dogs between the ages of 7 and 11 years will experience arthritis, 1 in 2 will get some form of cancer and 1 in 4 dogs will die from the disease. 61% of felines over the age of 6 have Arthritis in at least 1 joint and 30% will be affected by a tumour at some point in their lives.
The medication available to pets for these indications can provide negative side effects including nausea, loss of appetite, depression and internal bleeding. Pets are also becoming increasingly resistant to non-steroidal anti-inflammatory drugs and other pharmaceutical therapies.
CannPal is working to further explore the natural healing abilities of cannabinoids, to develop novel and efficacious therapies for your companions, without the associated negative side effects, to enhance their quality of life.
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is...
29th May 2018: Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “th...
Key Highlights CannPal has been granted export permits by Health Canada for its medical cannabis oil...